查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1608029

人類胚胎幹細胞市場：按類型、應用和最終用戶分類 - 全球預測 2025-2030

Human Embryonic Stem Cells Market by Type (Pluripotent Stem Cells, Totipotent Stem Cells, Unipotent Stem Cells), Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，人類胚胎幹細胞市值為8.4835億美元，預計2024年將達到9.2043億美元，複合年成長率為8.98%，預計2030年將達到15.4981億美元。

人類胚胎幹細胞（hESC）是一種源自早期人類胚胎的多功能細胞，可分化成任何細胞類型。其獨特的特性對於再生醫學、藥物發現和發育生物學至關重要。對 hESC 的需求在於它們有可能徹底改變帕金森氏症、糖尿病和心臟病等疾病的治療方法。這些細胞還可以應用於毒理學測試、基因研究和個人化醫療，以提供針對患者的治療方法。最終用戶包括專注於幹細胞研究的研究機構、生物技術公司和臨床研究組織。主要成長動力包括再生醫學的進步、政府和私人對幹細胞研究的資助增加，以及需要創新治療解決方案的慢性疾病的增加。此外，人們對精準醫療日益成長的興趣為使用 hESC 進行治療提供了有利可圖的機會。然而，圍繞 hESC 來源的倫理問題和監管障礙構成了重大挑戰。控制幹細胞分化的技術限制以及基於 hESC 的治療的高成本也阻礙了市場的成長。透過開發道德採購方法、增強分化技術和降低生產成本，有機會克服這些挑戰並擴大 hESC 的接受和應用。這個市場還有潛力進行合作研究，以共用技術並提高公眾對幹細胞效用的認知。隨著對先進治療解決方案的需求不斷增加，創新變得至關重要。重點領域包括改善細胞療法的基因工程、擴大生產規模以實現更廣泛的獲取，以及改進生物資訊學以實現更好的疾病建模。隨著相關人員解決倫理和監管問題、創建創新解決方案並適應個人化醫療和再生療法不斷變化的需求，hESC 市場充滿活力，並有望實現顯著成長。

主要市場統計
基準年[2023] 8.4835 億美元
預計年份 [2024] 92043萬美元
預測年份 [2030] 15.4981億美元
複合年成長率（%） 8.98%

市場動態：揭示快速發展的人類胚胎幹細胞市場的關鍵市場洞察

人類胚胎幹細胞市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 遺傳疾病迅速增加
    • 提高消費者對幹細胞療法在治療疾病方面的效用的認知
    • 再生醫學需求不斷成長
  • 市場限制因素
    • 治療費用上漲
  • 市場機會
    • 人類胚胎幹細胞正在進行的研究活動
    • 幹細胞治療技術開發
  • 市場挑戰
    • 嚴格的政府法規

波特五力：駕馭人類胚胎幹細胞市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解外部對人類胚胎幹細胞市場的影響

外部宏觀環境因素在塑造人類胚胎幹細胞市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解人類胚胎幹細胞市場的競爭狀況

人類胚胎幹細胞市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣人類胚胎幹細胞市場供應商的績效評估

FPNV定位矩陣是評估人類胚胎幹細胞市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了人類胚胎幹細胞市場的成功之路

人類胚胎幹細胞市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 遺傳病患病率迅速增加
      • 消費者越來越意識到幹細胞治療疾病的有效性
      • 對再生醫學的需求不斷增加
    • 抑制因素
      • 治療費用高
    • 機會
      • 人類胚胎幹細胞正在進行的研究活動
      • 幹細胞治療技術發展
    • 任務
      • 嚴格的政府規章制度
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 人類胚胎幹細胞市場：依類型

  • 多功能細胞
  • 全能幹細胞
  • 單能幹細胞

第7章 人類胚胎幹細胞市場：依應用分類

  • 再生醫學
  • 幹細胞生物學研究
  • 組織工程
  • 毒性試驗

第8章 人類胚胎幹細胞市場：依最終用戶分類

  • 臨床試驗
  • 調查

第9章美洲人類胚胎幹細胞市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區人類胚胎幹細胞市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲人胚胎幹細胞市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Astellas Pharma Inc.
  • Becton, Dickinson and Company
  • Biotime, Inc
  • CellGenix GmbH
  • International Stem Cell Corporation
  • Lineage Cell Therapeutics Inc.
  • Lonza Group AG
  • Merck KGaA
  • Novo Nordisk A/S
  • PeproTech Inc.
  • Pfizer Inc.
  • PromoCell GmbH
  • Qiagen NV
  • R&D Systems, Inc.
  • Smith & Nephew PLC
  • Stemcell Technologies Inc.
  • Sumanas, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • ViaCyte, Inc.
Product Code: MRR-AD36CD897E4B

The Human Embryonic Stem Cells Market was valued at USD 848.35 million in 2023, expected to reach USD 920.43 million in 2024, and is projected to grow at a CAGR of 8.98%, to USD 1,549.81 million by 2030.

Human Embryonic Stem Cells (hESCs) are pluripotent stem cells derived from early-stage human embryos capable of differentiating into any cell type. Their unique properties make them pivotal in regenerative medicine, drug discovery, and developmental biology. The necessity of hESCs lies in their potential to revolutionize disease treatment, particularly in conditions like Parkinson's, diabetes, and heart diseases, where they can help regenerate damaged tissues. Applications extend to toxicology testing, genetic research, and personalized medicine, as these cells offer patient-specific therapy avenues. End-users encompass institutes focusing on stem cell research, biotechnology companies, and clinical research organizations. Key growth drivers include advancements in regenerative medicine, increasing government and private funding for stem cell research, and rising prevalence of chronic diseases demanding innovative treatment solutions. Additionally, the growing interest in precision medicine opens lucrative opportunities for hESC-based therapies. However, ethical concerns surrounding the source of hESCs and regulatory hurdles present significant challenges. Technological limitations in controlling stem cell differentiation and high costs involved in hESC-based treatments also impede market growth. Opportunities exist in overcoming these challenges by developing ethical sourcing methods, enhancing differentiation techniques, and reducing production costs, thus widening the acceptance and application of hESCs. The market also holds potential in collaborations for technology sharing and increasing public awareness regarding stem cell benefits. With the growing demand for advanced therapeutic solutions, innovation is critical. Focus areas should include genetic engineering to improve cell therapies, upscaling manufacturing for broader access, and improving bioinformatics for better disease modeling. The hESC market is dynamic and poised for substantial growth as stakeholders address ethical and regulatory issues, create innovative solutions, and adapt to the evolving demand for personalized medicine and regenerative therapies.

KEY MARKET STATISTICS
Base Year [2023] USD 848.35 million
Estimated Year [2024] USD 920.43 million
Forecast Year [2030] USD 1,549.81 million
CAGR (%) 8.98%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Embryonic Stem Cells Market

The Human Embryonic Stem Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surge in the prevalence of genetic disorders
    • Growing awareness among consumers about the stem cell therapeutic potency for disease treatment
    • Increasing demand for the regenerative medicines
  • Market Restraints
    • High cost of treatment
  • Market Opportunities
    • Ongoing research activities in the human embryonic stem cells
    • Technological development in the stem cell therapy
  • Market Challenges
    • Strict rules and regulations of the government

Porter's Five Forces: A Strategic Tool for Navigating the Human Embryonic Stem Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Embryonic Stem Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Embryonic Stem Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Embryonic Stem Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Embryonic Stem Cells Market

A detailed market share analysis in the Human Embryonic Stem Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Embryonic Stem Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Embryonic Stem Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Embryonic Stem Cells Market

A strategic analysis of the Human Embryonic Stem Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Embryonic Stem Cells Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Becton, Dickinson and Company, Biotime, Inc, CellGenix GmbH, International Stem Cell Corporation, Lineage Cell Therapeutics Inc., Lonza Group AG, Merck KGaA, Novo Nordisk A/S, PeproTech Inc., Pfizer Inc., PromoCell GmbH, Qiagen NV, R&D Systems, Inc., Smith & Nephew PLC, Stemcell Technologies Inc., Sumanas, Inc., Takara Bio Inc., Thermo Fisher Scientific, Inc., and ViaCyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Human Embryonic Stem Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Pluripotent Stem Cells, Totipotent Stem Cells, and Unipotent Stem Cells.
  • Based on Application, market is studied across Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, and Toxicology Testing.
  • Based on End-User, market is studied across Clinical Trials and Research.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in the prevalence of genetic disorders
      • 5.1.1.2. Growing awareness among consumers about the stem cell therapeutic potency for disease treatment
      • 5.1.1.3. Increasing demand for the regenerative medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities in the human embryonic stem cells
      • 5.1.3.2. Technological development in the stem cell therapy
    • 5.1.4. Challenges
      • 5.1.4.1. Strict rules and regulations of the government
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Embryonic Stem Cells Market, by Type

  • 6.1. Introduction
  • 6.2. Pluripotent Stem Cells
  • 6.3. Totipotent Stem Cells
  • 6.4. Unipotent Stem Cells

7. Human Embryonic Stem Cells Market, by Application

  • 7.1. Introduction
  • 7.2. Regenerative Medicine
  • 7.3. Stem Cell Biology Research
  • 7.4. Tissue Engineering
  • 7.5. Toxicology Testing

8. Human Embryonic Stem Cells Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinical Trials
  • 8.3. Research

9. Americas Human Embryonic Stem Cells Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Human Embryonic Stem Cells Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Human Embryonic Stem Cells Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. Becton, Dickinson and Company
  • 3. Biotime, Inc
  • 4. CellGenix GmbH
  • 5. International Stem Cell Corporation
  • 6. Lineage Cell Therapeutics Inc.
  • 7. Lonza Group AG
  • 8. Merck KGaA
  • 9. Novo Nordisk A/S
  • 10. PeproTech Inc.
  • 11. Pfizer Inc.
  • 12. PromoCell GmbH
  • 13. Qiagen NV
  • 14. R&D Systems, Inc.
  • 15. Smith & Nephew PLC
  • 16. Stemcell Technologies Inc.
  • 17. Sumanas, Inc.
  • 18. Takara Bio Inc.
  • 19. Thermo Fisher Scientific, Inc.
  • 20. ViaCyte, Inc.

LIST OF FIGURES

  • FIGURE 1. HUMAN EMBRYONIC STEM CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HUMAN EMBRYONIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HUMAN EMBRYONIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN EMBRYONIC STEM CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN EMBRYONIC STEM CELLS MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TOTIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY UNIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY STEM CELL BIOLOGY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. HUMAN EMBRYONIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. HUMAN EMBRYONIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023